Kestra Private Wealth Services’s Neurogene NGNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-1,450
Closed -$30K 949
2022
Q2
$30K Buy
1,450
+250
+21% +$6.1K ﹤0.01% 891
2022
Q1
$45K Buy
1,200
+600
+100% +$35K ﹤0.01% 953
2021
Q4
$58K Buy
+600
New +$73.1K ﹤0.01% 972

Other funds holding NGNE

Kestra Private Wealth Services's NGNE Position: Q3 2022 in Review

Kestra Private Wealth Services sold out of Neurogene (NGNE) in Q3 2022, closing a stake of 1,450 shares — an estimated $30K sold.

Kestra Private Wealth Services first reported a position in NGNE in Q4 2021 and held it in 3 quarters. The position peaked at $58K in Q4 2021. 52 funds tracked by Wall St. Rank hold NGNE as of Q3 2022.

  • Kestra Private Wealth Services reported no remaining Neurogene position as of Q3 2022 after selling out during the quarter.
  • Kestra Private Wealth Services sold 1,450 Neurogene shares in Q3 2022, an estimated $30K.
  • Kestra Private Wealth Services first reported a position in Neurogene in Q4 2021 and held it in 3 quarters.
  • Kestra Private Wealth Services's Neurogene position peaked at $58K in Q4 2021.
  • 52 funds tracked by Wall St. Rank held Neurogene as of Q3 2022.

Based on Kestra Private Wealth Services's 13F filing for Q3 2022, filed 14 Nov 2022.